Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ADTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CEO (new) — The Chief Executive Officer resigned effective May 31, 2026, followed immediately by the COO's resignation.
Aditxt CEO Amro Albanna resigns; Jeffrey Busch named Interim CEO amid C-suite shakeup
Filed June 1, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
high
CEO Amro Albanna resigned effective May 31, 2026, and also stepped down from the Board of Directors. The company states his departure was not due to any disagreement on operations or policies.
Item 5.02 verify on EDGAR → -
high
Jeffrey M. Busch, 68, appointed Interim CEO effective May 31 with $500,000 annual salary. Busch previously founded Global Medical REIT (NYSE: GMRE) and currently leads Ignite Proteomics, an Aditxt subsidiary.
Item 5.02 verify on EDGAR → -
high
COO Rowena Albanna resigned effective June 5, 2026, marking the second C-suite departure within days of the CEO's exit.
Item 5.02 verify on EDGAR → -
medium
Two directors resigned: Amro Albanna (as part of CEO departure) and Dr. Shahrokh Shabahang. Dr. Shabahang remains as Chief Innovation Officer. Independent director Brian Brady appointed non-executive Chairman.
Item 5.02 verify on EDGAR → -
low
Company issued press release June 1, 2026 announcing the leadership changes under Regulation FD disclosure requirements.
Item 7.01 verify on EDGAR →
Summary
Aditxt disclosed a significant leadership transition with CEO Amro Albanna resigning effective May 31, 2026, after notifying the company on May 29. He also resigned from the Board of Directors on May 30. The Board moved quickly to appoint Jeffrey M. Busch as Interim CEO, a seasoned executive who founded Global Medical REIT and currently runs Aditxt subsidiary Ignite Proteomics.
The company emphasized that Albanna's departure was not due to any disagreement on operations or policies. The leadership shakeup extends beyond the CEO role. COO Rowena Albanna resigned effective June 5, and two directors departed, though Dr. Shahrokh Shabahang remains as Chief Innovation Officer.
Independent director Brian Brady was elevated to non-executive Chairman, providing board continuity during the transition. For retail investors, the rapid succession of C-suite departures raises questions about strategic direction and operational stability. Watch for the company's next quarterly earnings call or investor update for management's explanation of the transition plan and strategic priorities under new leadership. The interim nature of Busch's appointment suggests a CEO search may be underway, which could signal further changes ahead.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 31, 2026, the Board appointed Brian Brady, an independent director of the Company, to serve as non-executive Chairman of the Board, effective as of such date.
Brian Brady, an existing independent director, was appointed non-executive Chairman of the Board effective May 31, 2026, providing board leadership continuity during the CEO transition.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 1, 2026, the Company issued a press release announcing the matters described in Item 5.02 of this Current Report on Form 8-K.
The company issued a press release on June 1, 2026 regarding matters disclosed in Item 5.02 of this 8-K. Item 5.02 typically covers departures or appointments of directors or principal officers, changes in fiscal year, or amendments to articles of incorporation or bylaws. The specific content of the press release and Item 5.02 disclosure are not provided in this excerpt.
Event · Item 9.01 — Financial Statements and Exhibits
Aditxt filed an 8-K to furnish a press release dated June 1, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1
Press Release of Aditxt, Inc., dated June 1, 2026 (furnished herewith)
The company furnished a press release dated June 1, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify